

# PROVIDER BULLETIN

## PROVIDER INFORMATION



February 8, 2023

### MHCP Pharmacy Benefit Exclusion for Briumvi™, Hemgenix®, Lunsumio™, Rebyota™, Sunlenca® Injection, and Vivimusta

Effective **February 8, 2023**, the drugs listed in the table below will be excluded from pharmacy benefit coverage due to clinician-administered route of administration and may be available for medical benefit coverage for subscribers who are eligible.

Drug Name
Briumvi™ (ublituximab-xiyy) solution for intravenous (IV) infusion
Hemgenix® (etranacogene dezaparvovec-drlb) suspension for intravenous (IV) infusion
Lunsumio™ (mosunetuzumab-axgb) solution for intravenous (IV) infusion
Rebyota™ (fecal microbiota, live–jslm) suspension for rectal administration
Sunlenca® (lenacapavir sodium injection) solution for subcutaneous (SQ) injection
Vivimusta (bendamustine hydrochloride) solution for intravenous (IV) infusion

#### Products Impacted

These exclusions apply to Minnesota Health Care Programs:

- Families and Children [*formerly known as* Prepaid Medical Assistance Program (PMAP)]
- MinnesotaCare (MNCare)
- Minnesota Senior Care Plus (MSC+)

#### Questions?

If you have questions for a member enrolled in a Minnesota Health Care Programs (MHCP) plan, please contact provider services at **1-866-518-8448**. For all other questions, contact provider services at **(651) 662-5200** or **1-800-262-0820**.